Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beloranib in Prader-Willi Syndrome
NCT02179151Phase 3Terminated
- Sponsor
- Zafgen, Inc.
- Start
- Sep 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of beloranib in Prader-Willi syndrome (PWS), sponsored by Zafgen, Inc.. Started Sep 2014; status: terminated.
02
Drugs
beloranib
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on NCT02179151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02179151.